Program
Pexerelgon
Also written as “AZD5462”, “AZD5462 film-coated tablet” and “[14C]AZD5462 Solution for Infusion”.
Its studies are mostly in Heart Failure · Renal Insufficiency, led by AstraZeneca.
Furthest: phase 2, since Feb 16, 20247 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 70 open or running | phase 2since Feb 16, 2024 | Jul 29, 2021 | none ahead |
- Named in AstraZeneca’s own pipeline as
AZD5462
, phase 2, as of Oct 30, 2026 (source).
Also a collaborator on its studies: parexel and quotient-sciences.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 29, 2021First study: phase 1 study in Healthy ParticipantsFirst studyNCT04994106 · 98 enrolled · United States
- May 24, 2022Phase 1 study in Healthy ParticipantsNCT05395117 · 32 enrolled · United States
- Aug 22, 2022Phase 1 study in Healthy ParticipantsNCT05512806 · 16 enrolled · United States
- Feb 16, 2024Phase 2 study in Chronic Heart FailureNCT06299826 · 375 enrolled · United States, Bulgaria, Czechia and more
- Sep 13, 2024Phase 1 study in Renal InsufficiencyNCT06639087 · 8 enrolled · Bulgaria
- Oct 25, 2024Phase 1 study in Renal InsufficiencyNCT06661733 · 16 enrolled · Bulgaria
- May 5, 2025Phase 1 study in Heart FailureNCT06989983 · 8 enrolled · United Kingdom
TargetBeta
“A mimetic of the endogenous heterodimeric insulin-like peptide relaxin, with potential vasodilating, cardioprotective and anti-fibrotic activities. Upon administration, pexerelgon mimics relaxin and may bind to relaxin receptor 1 (relaxin family peptide receptor 1; RXFP1). This may activate multi…”NCIt, read by Claude
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06989983Heart Failure · United Kingdom | 1 | Completed | Jun 25, 2025 | 8 |
| NCT06661733Renal Insufficiency · Bulgaria | 1 | Completed | Dec 23, 2024 | 16 |
| NCT06639087Renal Insufficiency · Bulgaria | 1 | Terminated | May 29, 2025 | 8 |
| NCT06299826Chronic Heart Failure · United States, Bulgaria, Czechia and more | 2 | Completed | Feb 10, 2026 | 375 |
| NCT05512806Healthy Participants · United States | 1 | Completed | Nov 7, 2022 | 16 |
| NCT05395117Healthy Participants · United States | 1 | Completed | Sep 12, 2022 | 32 |
| NCT04994106Healthy Participants · United States | 1 | Completed | Sep 20, 2022 | 98 |
How it is read
Names in the registry
- “AZD5462”, 6 entries
- “AZD5462 film-coated tablet”, 1 entry
- “[14C]AZD5462 Solution for Infusion”, 1 entry
- “[14C]AZD5462 Oral Solution”, 1 entry
Conditions, from the studies’ own filings
- Heart Failure, 2 studies
- Renal Insufficiency, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.